Crowe, Jr.
Donald Raymond Crowe, Jr., Dodgeville, WI US
Patent application number | Description | Published |
---|---|---|
20110294004 | ALKALINE CELL WITH ADDITIVE FOR IMPROVED DISCHARGE PERFORMANCE - The present disclosure generally relates to an alkaline electrochemical cell comprising an additive for improved discharge performance. The additive is a finely dispersed superabsorbent material comprising particles having a substantially uniform shape and a small particle size relative to typical materials used in alkaline cells. The superabsorbent material results in enhanced discharge performance of the alkaline cell by increasing access of zinc to the electrolyte. | 12-01-2011 |
James E. Crowe, Jr., Nashville, TN US
Patent application number | Description | Published |
---|---|---|
20090092609 | MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS AND USES THEREFOR - The present invention is directed to particular human monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of respiratory syncytial virus infections. In particular, these antibodies may neutralize RSV. Also disclosed are improved methods for producing monoclonal antibodies. | 04-09-2009 |
20090162395 | VACCINE FOR RSV AND MPV - The present invention is directed to alphavirus vectored vaccine contructs encoding paramyxovirus proteins that find use in the prevention of respiratory syncytial virus or human metapneumovirus infections. In particular, these vaccines induce cellular and humoral immune responses that inhibit RSV. Also disclosed are improved methods for producing alphavirus vectored paramyxovirus vaccines. | 06-25-2009 |
20100040650 | Virus-Like paramyxovirus particles and vaccines - The present invention is directed to alphavirus virus-like particles produced by synthesizing in cell, including in vivo, structural proteins in the absence of other alphavirus proteins. In particular, these virus-like particules vaccines induce cellular and humoral immune responses that can block or inhibit alphavirus infections. Also disclosed are methods of vaccinating subjects with virus-like particles and vectors encoding the same. | 02-18-2010 |
20120100142 | MONOCLONAL ANTIBODIES TO INFLUENZA H1N1 VIRUS USES THEREOF - The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of influenza virus infections. In particular, these antibodies may neutralize or limit the replication of H1N1 influenza virus. Also disclosed are improved methods for producing such monoclonal antibodies. | 04-26-2012 |
James E. Crowe, Jr., Brentwood, TN US
Patent application number | Description | Published |
---|---|---|
20090110684 | Neutralizing monoclonal antibodies to respiratory syncytial virus - The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention. | 04-30-2009 |
20120087909 | NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS - The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention. | 04-12-2012 |